Diabetic Medicine

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

By Julia Fielden, Pam LeBlanc, Chloe Parezanovic, David J. T. Campbell

Study in peoplePopulations

The paper

Julia Fielden, Pam LeBlanc, Chloe Parezanovic, David J. T. Campbell

Université de Montréal; University of Calgary

Diabetic Medicine, 4 Sep 2026

doi.org/10.1111/dme.70463 PubMed 42698185

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs